XOMA Royalty (XOMA) Common Equity (2010 - 2026)
XOMA Royalty (XOMA) reported Common Equity of $92.9 million for Q1 2026, up 43.75% on a YoY basis from $64.6 million in Q1 2025, and up 10.64% sequentially from $83.9 million in Q4 2025.
XOMA Royalty (XOMA) Common Equity (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Common Equity data on file, last reported at $92.9 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 43.75% year-over-year to $92.9 million; the trailing twelve-month figure through Mar 2026 stood at $92.9 million (up 43.75% YoY), and the FY2025 full-year result was $83.9 million, up 35.6% from the prior year.
- Common Equity rose to $92.9 million in Q1 2026, from $83.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $139.9 million in Q1 2022 to a low of $61.9 million in Q4 2024.
- A 5-year average of $94.5 million and a median of $88.4 million in 2025 frame the typical range for Common Equity.
- Across the five-year window, Common Equity jumped 71.22% in 2022 and plunged 45.58% in 2024, its largest moves.
- Tracing XOMA's Common Equity over 5 years: stood at $124.0 million in 2022, then sank by 44.6% to $68.7 million in 2023, then retreated by 9.9% to $61.9 million in 2024, then soared by 35.6% to $83.9 million in 2025, then grew by 10.64% to $92.9 million in 2026.
- Business Quant data shows XOMA's Common Equity at $92.9 million in Q1 2026, $83.9 million in Q4 2025, and $72.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 92.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.88 Mn |
| Dec 31, 2025 | 83.94 Mn |
| Jun 30, 2025 | 72.44 Mn |
| Mar 31, 2025 | 64.61 Mn |
| Dec 31, 2024 | 61.90 Mn |
| Sep 30, 2024 | 64.79 Mn |
| Jun 30, 2024 | 79.97 Mn |
| Mar 31, 2024 | 62.32 Mn |
| Dec 31, 2023 | 68.70 Mn |
| Sep 30, 2023 | 105.96 Mn |
| Jun 30, 2023 | 110.12 Mn |
| Mar 31, 2023 | 114.53 Mn |
| Dec 31, 2022 | 124.01 Mn |
| Sep 30, 2022 | 130.33 Mn |
| Jun 30, 2022 | 134.96 Mn |
| Mar 31, 2022 | 139.92 Mn |
| Dec 31, 2021 | 141.88 Mn |
| Sep 30, 2021 | 111.58 Mn |
| Jun 30, 2021 | 116.58 Mn |
| Mar 31, 2021 | 81.72 Mn |